Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the expression of accessory molecules to address these challenges. Current systems rely on constitutive transgene expression or multiple viral vectors, resulting in unregulated response and product heterogeneity. Here, we develop a genetic platform that combines autonomous antigen-induced production of an accessory molecule with constitutive CAR expression in a single lentiviral vector called Uni-Vect. The broad therapeutic application of Uni-Vect is demonstrated in vivo by activation-dependent expression of (1) an immunostimulatory cytokine that improves efficacy, (2) an antibody that ameliorates cytokine-release syndrome, and (3) transcription factors that modulate T cell biology. Uni-Vect is also implemented as a platform to characterize immune receptors. Overall, we demonstrate that Uni-Vect provides a foundation for a more clinically actionable next-generation cellular immunotherapy.

Expression of inducible factors reprograms CAR-T cells for enhanced function and safety / Smole, Anže; Benton, Alexander; Poussin, Mathilde A; Eiva, Monika A; Mezzanotte, Claudia; Camisa, Barbara; Greco, Beatrice; Sharma, Prannda; Minutolo, Nicholas G; Gray, Falon; Bear, Adham S; Baroja, Miren L; Cummins, Casey; Xu, Chong; Sanvito, Francesca; Goldgewicht, Andrea Lang; Blanchard, Tatiana; Rodriguez-Garcia, Alba; Klichinsky, Michael; Bonini, Chiara; June, Carl H; Posey, Avery D; Linette, Gerald P; Carreno, Beatriz M; Casucci, Monica; Powell, Daniel J. - In: CANCER CELL. - ISSN 1535-6108. - 40:12(2022), pp. 1470-1487. [10.1016/j.ccell.2022.11.006]

Expression of inducible factors reprograms CAR-T cells for enhanced function and safety

Greco, Beatrice;Bonini, Chiara;
2022-01-01

Abstract

Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the expression of accessory molecules to address these challenges. Current systems rely on constitutive transgene expression or multiple viral vectors, resulting in unregulated response and product heterogeneity. Here, we develop a genetic platform that combines autonomous antigen-induced production of an accessory molecule with constitutive CAR expression in a single lentiviral vector called Uni-Vect. The broad therapeutic application of Uni-Vect is demonstrated in vivo by activation-dependent expression of (1) an immunostimulatory cytokine that improves efficacy, (2) an antibody that ameliorates cytokine-release syndrome, and (3) transcription factors that modulate T cell biology. Uni-Vect is also implemented as a platform to characterize immune receptors. Overall, we demonstrate that Uni-Vect provides a foundation for a more clinically actionable next-generation cellular immunotherapy.
2022
CAR-T Cells
CRS
IL-12
IL-6
NFAT
TCR
armored
inducible
single lentiviral expression system
transcription factor
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/134736
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact